Drugs / Adjuvanted trivalent inactivated subunit influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00644059 | Nov 2007 → Apr 2010 | influenza | Novartis | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adjuvanted trivalent inactivated subunit influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00644059 ↗ |
| Known as | ATIV | “The absolute vaccine efficacy rates against all influenza strains (94 of 110 cases were due to vaccine-matched H3N2 viruses) were 86% (95% confidence interval [CI], 74 to 93)...” PMID 21995388 ↗ Oct 2011 |
| Modality | Vaccine | “This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine” NCT00644059 ↗ |
| Route | Intramuscular | “two intramuscular (IM) injections of half dose or one IM injection of full dose” NCT00644059 ↗ |